In vivo gene delivery of glial cell line-derived neurotrophic factor for Parkinson's disease

Annals of Neurology

Volumn 53, Issue SUPPL. 3, 2003, Pages

  Kordower, Jeffrey H ^a   Isacson, ^b   Brooks, ^b   Olanow, ^b   Hunot, ^b   Stocchi, ^b   Jenner, ^b   Rascol, ^b   Marek, ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Rush Presbyterian Medical Center ^*

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; BROMOCRIPTINE; CLOZAPINE; DNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; ROPINIROLE;

ANOREXIA; CLINICAL TRIAL; DEPRESSION; DOPAMINERGIC NERVE CELL; DOSE RESPONSE; GENE DELIVERY SYSTEM; GENE THERAPY; HALLUCINATION; HISTOPATHOLOGY; HUMAN; LEWY BODY; LHERMITTE DUCLOS DISEASE; NAUSEA; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT;

ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CAUDATE NUCLEUS; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; GENE THERAPY; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PUTAMEN; SUBSTANTIA NIGRA;

EID: 0037378036     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.10485     Document Type: Review

References (39)

1. Parkinson's Study Group. DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Arch Neurol 1989;46:1052-1060.
2. Shoulson I. DATATOP: a decade of neuroprotective inquiry. Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism. Ann Neurol 1998;44:S160-S166.
3. Fahn S. Controversies in the therapy of Parkinson's disease. Adv Neurol 1996;69:477-486.
4. Olanow CW, Hauser RA, Gauger L, et al. Effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
5. Levi-Montalcini R, Meyer H, Hamburger V. In vitro experiments on the effects of mouse sarcoma 180 and 37 on spinal sympathetic ganglia of the chick embryo. Cancer Res 1954;14:49-57.
6. Tuszynski M. Neurotrophic factors. In: Tuzynski M, Kordower JH, eds. CNS regeneration: basic science and clinical advances. New York: Academic Press 1999:109-158.
7. Olson L, Nordberg A, von Holst H, et al. Nerve growth factor affects 11 C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect 1992;4:79-95.
8. Collier T, Sortwell CE. Therapeutic potential of nerve growth factors in Parkinson's disease. Drugs Aging 1999;14:261-287.
9. Lin LF, Doherty DH, Lile JD, et al. GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993;260:1130-1132.
10. Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line-derived neurotrophic factor reverses toxin-induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994;182:107-111.
11. Hebert MA, Hoffer BJ, Zhang Z, et al. Functional effects of GDNF in normal and parkinsonian rats and monkeys. In: Tuszynski M, Kordower JH, eds. CNS regeneration: basic science and clinical advances. New York: Academic Press, 1999:419-436.
12. Kordower JH, Palfi S, Chen E, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol 1999;46:419-424.
13. Lapchak PA, Araujo DM, Hilt DC, et al. Topographical distribution of [125I]-glial cell line-derived neurotrophic factor in unlesioned and MPTP-lesioned rhesus monkey brain following a bolus intraventricular injection. Brain Res 1998;789:9-22.
14. Choi-Lundberg DL, Lin Q, Chang YN, et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 1997;275:838-841.
15. Bilang-Bleuel A, Revah F, Colin P, et al. Intrastriatal injection of an adenoviral vector expressing glial cell line-derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson's disease. Proc Natl Acad Sci 1997;94:8818-8823.
16. Connor B, Kozlowski DA, Schallert T, et al. Differential effects of glial cell line-derived neurotrophic factor (GDNF) in the striatum and substantia nigra of the aged Parkinsonian rat. Gene Ther 1999;6:1936-1951.
17. Lapchak PA, Araujo DM, Hilt DC, et al. Adenoviral vector-mediated GDNF gene therapy in a rodent lesion model of late stage Parkinson's disease. Brain Res 1997;777:153-160.
18. Connor B. Adenoviral vector-mediated delivery of glial cell line-derived neurotrophic factor provides neuroprotection in the aged parkinsonian rat. Clin Exp Pharmacol Physiol 2001;28:896-900.
19. Gorellou P, Mallet J. Gene therapy for Parkinson's disease. Mol Neurobiol 1997;15:241-256.
20. Bjorklund A, Kirik D, Rosenblad C, et al. Towards a neuroprotective gene therapy for Parkinson's disease: use of adenovirus, AAV and lentivirus vectors for gene transfer of GDNF to the nigrostriatal system in the rat Parkinson model. Brain Res 2000;886:82-98.
21. Mandel RJ, Spratt SK, Snyder RO, et al. Midbrain injection of recombinant adeno-associated virus encoding rat glial cell line-derived neurotrophic factor protects nigral neurons in a progressive 6-hydroxydopamine-induced degeneration model of Parkinson's disease in rats. Proc Natl Acad Sci 1997;94:14083-14088.
22. Mandel RJ, Snyder RO, Leff SE. Recombinant adeno-associated viral vector-mediated glial cell line-derived neurotrophic factor gene transfer protects nigral dopamine neurons after onset of progressive degeneration in a rat model of Parkinson's disease. Exp Neurol 1999;160:205-214.
23. Kirik D, Rosenblad C, Bjorklund A. Preservation of a functional nigrostriatal dopamine pathway by GDNF in the intrastriatal 6-OHDA lesion model depends on the site of administration of the trophic factor. Eur J Neurosci 2000;12:3871-3882.
24. Kirik D, Rosenblad C, Bjorklund A, et al. Long-term rAAV-mediated gene transfer of GDNF in the rat Parkinson's model: intrastriatal but not intranigral transduction promotes functional regeneration in the lesioned nigrostriatal system. J Neurosci 2000;20:4686-4700.
25. Bankiewicz KS, Eberling JL, Kohutnicka M, et al. Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 2000;164:2-14.
26. Deglon N, Tseng JL, Bensadoun JC, et al. Seof-inactivating lentiviral vectors with enhanced transgene expression as a potential gene transfer system in Parkinson's disease. Hum Gene Ther 2000;11:170-190.
27. Georgievska B, Kirik D, Rosenblad C, et al. Neuroprotection in the rat Parkinson model by intrastriatal GDNF gene transfer using a lentiviral vector. Neuroreport 2002;13:75-82.
28. Kordower JH, Bloch J, Ma SY, et al. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 2000;160:1-16.
29. Emborg ME, Ma SY, Mufson EJ, et al. Age-related declines in nigral neuronal function correlate with motor impairments in Rhesus monkeys. J Comp Neurol 1998;401:253-265.
30. Quinn N, Parkes D, Janota I, et al. Preservation of the substantia nigra and locus coeruleus in a patient receiving levodopa (2 kg) plus decarboxylase inhibitor over a four-year period. Mov Disord 1986;1:65-68.
31. Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000;290:767-773.
32. Kordower JH, Liu YT, Winn S, et al. Encapsulated PC12 cell transplants into hemiparkinsonian monkeys: a behavioral, neuroanatomical and neurochemical analysis. Cell Transplant 1995;4:155-171.
33. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
34. Vigna E, Cavalieri S, Ailles L, et al. Robust and efficient regulation of transgene expression in vivo by improved tetracycline-dependent lentiviral vectors. Mol Ther 2002;3:252-261.
35. Blesch A, Conner JM, Tuszynski MH. Modulation of neuronal survival and axonal growth in vivo by tetracycline-regulated neurotrophin expression. Gene Ther 2001;12:954-960.
36. Olanow CW, Kordower JH, Freeman TB. Fetal nigral transplantation for the treatment of Parkinson's disease. Trends Neurosci 1996;19:102-108.
37. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Engl J Med 1995;332:1118-1124.
38. Carvey PM. Drug actions in the central nervous system. New York: Oxford University Press, 1998:251-278.
39. During MJ, Kaplitt MG, Stern MB, Eidelberg D. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 2001;12:1589-1591.